Uncontrolled allergic rhinitis during treatment and its impact on quality of life: A cluster randomized trial

We thank Michael Hanna, PhD, Mercury Medical Research & Writing, for providing medical writing and data visualization services. Markus Magerl, MD Petra Staubach, MD Sabine Altrichter, MD Elena Ardelean, MD Karoline Krause, MD Martin Metz, MD Karsten Weller, MD Marcus Maurer, MD From the Department of Dermatology and Allergy, Allergie-Centrum-Charite, Charite– Universitatsmedizin Berlin, Berlin; and the Department of Dermatology, Universitatsmedizin Mainz, Mainz, Germany. E-mail: marcus.maurer@charite.de. Disclosure of potential conflict of interest: M. Maurer is or recently was a speaker and/or advisor for Almirall Hermal, Bayer, Schering Pharma, Biofrontera, Essex Pharma, Genentech, JADO Technologies, Jerini, Merckle Recordati, Novartis, Sanofi Aventis, Schering-Plough, Leo, MSD, Merck, Shire, Symbiopharm, UCB, and Uriach M. Magerl is or recently was a speaker for Almirall, Essex Pharma, and Jerini/Shire. M. Metz has been a speaker for Uriach and Essex Pharma. M. Metz is or recently was a speaker for Essex, MSD, Uriach, Merckle Recordati, Novartis. S. Altrichter, E. Ardelean, K. Krause, P. Staubach, and K. Weller declare no conflict of interests.